The following 30-second video demonstrates how our technology works:
Intellectual Property
TheraBiome owns five issued US patents and 19 international patents on its proprietary platform technology. Patents protect drug and biologic delivery, including vaccines.
Differentiated Drug Delivery Target Product Profile (TPP)
- TheraBiome's GEMICEL® platform technology is Phase II-ready based on its strong science and human proof-of-concept clinical studies compliant with FDA and international regulatory standards.
- This technology is suitable for delivery of small molecules and biologics including vaccines.
- Longer acting and locally delivered.
- TheraBiome is ready to support CMC strategy and deliverables.
- Disease and therapeutic area agnostic despite special focus on GI-related indications.
- Easy to swallow - patient compliant products.
© Copyright 2025. All rights reserved.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.